A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC.

Exclusion Criteria

• •Previous received anti-VEGFR small molecule tyrosine kinase inhibitors (e.g. famitinib, sorafenib, Sunitinib, regorafenib, etc.) for treatment of the patients .
• •A history of bleeding, any serious bleeding events.
• •Important blood vessels around tumors has been infringed and high risk of bleeding.
• •Coagulant function abnormality
• •artery/venous thromboembolism event
• •History of autoimmune disease
• •Positive test for human immunodeficiency virus
• •Active hepatitis B or hepatitis C
• •Uncontrolled pleural effusion and ascites • Known central nervous system (CNS) disease.
• •Long-term unhealing wound or incomplete healing of fracture
• •urine protein ≥2+ and 24h urine protein quantitative \> 1 g.
• •Pregnancy or lactation.
• •Thyroid dysfunction.
• •Peripheral neuropathy grade ≥2.
• •People with high blood pressure;
• •A history of unstable angina;
• •New diagnosis of angina pectoris.
• •Myocardial infarction incident ;